Seres Therapeutics Inc (MCRB)

0.7083 -0.0021 (-0.30%)
Closed USD Disclaimer
0.6916 -0.0167 (-2.36%)

Seres Therapeutics Inc Company Profile

Sector
Healthcare
Employees
431
Equity Type
ORD
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Contact Information
Address
Cambridge,02140 United States
Phone
617 945 9626
Fax
-
Top Executives
Name
Age
Since
Title
Richard N. Kender 68 2014 Independent Director
Eric D. Shaff 48 2014 President, CEO & Director
Dennis Arthur Ausiello 79 2015 Independent Director
Mark H. Wilcox 0 2015 Member of Scientific Advisory Board
Andrew Goodman 0 0000 Member of Scientific Advisory Board
Curtis Huttenhower 0 0000 Member of Scientific Advisory Board
Willard H. Dere 70 2017 Independent Director
Kurt C. Graves 56 2015 Independent Director
Stephen A. Berenson 63 2019 Independent Chairman
Claire M. Fraser-Liggett 69 2023 Independent Director
Paul R. Biondi 54 2020 Independent Director
Robert Jenq 0 0000 Member of Scientific Advisory Board
Marcel R.M. van den Brink 0 0000 Member of Scientific Advisory Board
Elhanan Borenstein 0 0000 Member of Scientific Advisory Board
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.